GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650
30. August 2022 18:00 ET
|
GT Biopharma, Inc.
GTB-3650’s IND application with the FDA expected by end of first quarter of 2023 BRISBANE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a...
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update
11. August 2022 09:35 ET
|
GT Biopharma, Inc.
Presented preclinical data demonstration second-generation CD19 targeting Tri-specific Killer Engager (TRIKE®) driving robust NK cell function against B cell malignancies at EHA 2022 Congress.GTB-5550...
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress
10. Juni 2022 08:00 ET
|
GT Biopharma, Inc.
Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivoFuture studies will also involve assessments of GTB-7550 TriKE efficacy in other hematologic cancers BRISBANE,...
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update
16. Mai 2022 08:01 ET
|
GT Biopharma, Inc.
Presented pre-clinical data at American Association for Cancer Research (AACR 2022), demonstrating GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) driving NK cell activation and...
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference
12. Mai 2022 08:00 ET
|
GT Biopharma, Inc.
BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary...
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022
11. April 2022 07:30 ET
|
GT Biopharma, Inc.
- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo- Future studies will also involve assessments of the B7H3 TriKE efficacy in the HNSCC tumor...
GT Biopharma Announces Closing of Private Placement Financing and Provides Business Update
06. Februar 2019 16:01 ET
|
GT Biopharma, Inc.
Corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational 2019 Company on track to report topline Phase 2a data of GTB-1550 this quarter ...
GT Biopharma, Inc. to Present at Biotech Showcase™ 2019
20. Dezember 2018 08:22 ET
|
GT Biopharma, Inc.
– Presentation with live audio webcast, Tuesday, January 8, 2019 at 11:30 AM PST – LOS ANGELES, Dec. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT...
GT Biopharma Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition
06. Dezember 2018 08:05 ET
|
GT Biopharma, Inc.
– Company’s proprietary TriKE product candidates have the potential to serve as a relatively safe, cost-effective, and easy-to-use therapy for refractory/relapsed AML, high-risk MDS and advanced...
GT Biopharma Announces Presentation of Two Abstracts at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition
20. November 2018 07:30 ET
|
GT Biopharma, Inc.
LOS ANGELES, Nov. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on...